keyword
MENU ▼
Read by QxMD icon Read
search

Liraglutide and obesity

keyword
https://www.readbyqxmd.com/read/28074747/liraglutide-a-glucagon-like-peptide-1-agonist-for-chronic-weight-management
#1
Kendra R Manigault, Maria Miller Thurston
OBJECTIVE: To review the efficacy and safety of liraglutide 3.0 mg for weight loss. DATA SOURCE: A literature search was performed using PubMed and MEDLINE from 2000 to 2016. The following key terms were used alone or in combination: glucagon-like peptide-1 agonist, liraglutide, obesity, overweight, and weight loss. Additional supporting literature was identified utilizing the reference lists of the preceding articles. STUDY SELECTION: Analyzed studies were published in English and investigated use of liraglutide and its impact on weight loss...
December 1, 2016: Consultant Pharmacist: the Journal of the American Society of Consultant Pharmacists
https://www.readbyqxmd.com/read/28074109/improvement-of-quality-of-life-through-glycemic-control-by-liraglutide-a-glp-1-analog-in-insulin-naive-patients-with-type-2-diabetes-mellitus-the-page1-study
#2
Hitoshi Ishii, Tetsuji Niiya, Yasuhiro Ono, Naoyuki Inaba, Hideaki Jinnouchi, Hirotaka Watada
BACKGROUND: In addition to achieving good glycemic control, diabetes care management aims to improve the quality of life (QOL) in patients. Treatment-associated difficulties and side effects frequently cause deterioration in QOL. Liraglutide, a GLP-1 receptor agonist, is a novel injection drug that promotes insulin secretion. It is a user-friendly, once-daily injection with fewer hypoglycemic events. In this study, we aimed to examine the effect of liraglutide therapy on QOL in patients...
2017: Diabetology & Metabolic Syndrome
https://www.readbyqxmd.com/read/28057699/glucagon-like-peptide-1-and-its-analogues-act-in-the-dorsal-raphe-and-modulate-central-serotonin-to-reduce-appetite-and-body-weight
#3
Rozita H Anderberg, Jennifer E Richard, Kim Eerola, Lorena Lopez Ferreras, Elin Banke Nordbeck, Caroline Hansson, Hans Nissbrandt, Filip Berqquist, Fiona M Gribble, Frank Reimann, Ingrid Wernstedt-Asterholm, Christophe Lamy, Karolina P Skibicka
Glucagon-like peptide-1 (GLP-1) and serotonin play critical roles in energy balance regulation. Both systems are exploited clinically as anti-obesity strategies. Surprisingly whether they interact in order to regulate energy balance is poorly understood. Here we investigated mechanisms by which GLP-1 and serotonin interact at the level of the CNS. Serotonin depletion impaired the ability of exendin-4, a clinically utilized GLP-1 analogue, to reduce body weight in rats, suggesting serotonin is a critical mediator of the energy balance impact of GLP-1R activation...
January 5, 2017: Diabetes
https://www.readbyqxmd.com/read/28049736/glp-1-analogue-induced-weight-loss-does-not-improve-obesity-induced-at-dysfunction
#4
Emilie Pastel, Laura J McCulloch, Rebecca Ward, Shivam Joshi, Kim M Gooding, Angela C Shore, Katarina Kos
Glucagon-like peptide-1 (GLP-1) analogues aid weight loss which improves obesity-associated adipose tissue (AT) dysfunction. GLP-1 treatment may however also directly influence AT which expresses GLP-1 receptors. This study aimed to assess the impact of GLP-1 analogue treatment on subcutaneous AT inflammatory and fibrotic responses, compared to weight loss by calorie reduction (control). Among the 39 participants with type 2 diabetes recruited, 30 age-matched participants were randomised to 4 months treatment with Liraglutide (n=22) or calorie restriction-based on dietetic counselling (n=8)...
January 3, 2017: Clinical Science (1979-)
https://www.readbyqxmd.com/read/28031776/glucagon-like-peptide-1-in-the-pathophysiology-and-pharmacotherapy-of-clinical-obesity
#5
REVIEW
Ananthi Anandhakrishnan, Márta Korbonits
Though the pathophysiology of clinical obesity is undoubtedly multifaceted, several lines of clinical evidence implicate an important functional role for glucagon-like peptide 1 (GLP-1) signalling. Clinical studies assessing GLP-1 responses in normal weight and obese subjects suggest that weight gain may induce functional deficits in GLP-1 signalling that facilitates maintenance of the obesity phenotype. In addition, genetic studies implicate a possible role for altered GLP-1 signalling as a risk factor towards the development of obesity...
December 15, 2016: World Journal of Diabetes
https://www.readbyqxmd.com/read/28007055/physiological-and-pathophysiological-aspects-of-incretin-hormones-and-glucagon
#6
Jonatan Ising Bagger
Infusion of oxyntomodulin and the separate and combined infusion of GLP-1 and glucagon inhibited food intake similarly in healthy individuals, with no superior effect of combining GLP-1 and glucagon. We confirm the inhibitory effects of oxyntomodulin and GLP-1, respectively, on GE and appetite scores observed previously, but by adding glucagon to the infusion of GLP-1 we found no additive effects. Unexpectedly, glucagon alone had no effect on GE and appetite scores, but inhibited food intake to the same extent as oxyntomodulin, GLP-1 and GLP-1 + glucagon...
January 2017: Danish Medical Journal
https://www.readbyqxmd.com/read/28003008/glucagon-like-peptide-1-glp-1-receptor-agonists-in-the-treatment-of-obese-women-with-polycystic-ovary-syndrome
#7
Themistoklis Tzotzas, Spyridon N Karras, Niki Katsiki
Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in females and is often associated with a number of cardiometabolic disorders such as central obesity, dyslipidaemia, hypertension, insulin resistance, hyperinsulinaemia, glucose intolerance and type 2 diabetes mellitus (T2DM). Glucagon-like peptide-1 (GLP-1), a gut hormone secreted after a meal, enhances glucose-stimulated insulin secretion and additionally suppresses appetite and gastric motility. Most studies found impaired GLP-1 kinetics in obese individuals, whereas small studies in PCOS reported reduced, normal or even elevated GLP-1 levels...
December 21, 2016: Current Vascular Pharmacology
https://www.readbyqxmd.com/read/27979579/liraglutide-in-an-adolescent-population-with-obesity-a-randomized-double-blind-placebo-controlled-5-week-trial-to-assess-safety-tolerability-and-pharmacokinetics-of-liraglutide-in-adolescents-aged-12-17-years
#8
Thomas Danne, Torben Biester, Kerstin Kapitzke, Sanja H Jacobsen, Lisbeth V Jacobsen, Kristin C Carlsson Petri, Paula M Hale, Olga Kordonouri
OBJECTIVES: To investigate the safety, tolerability, and pharmacokinetics of liraglutide in adolescents with obesity. STUDY DESIGN: This was a randomized, double-blind, placebo-controlled trial. Twenty-one subjects, aged 12-17 years and Tanner stage 2-5, with obesity (body mass index [BMI] corresponding to both a BMI ≥95th percentile for age and sex and to a BMI of ≥30 kg/m(2) for adults; additionally, BMI was ≤45 kg/m(2)) were randomized (2:1) to receive 5 weeks of treatment with liraglutide (0...
December 13, 2016: Journal of Pediatrics
https://www.readbyqxmd.com/read/27943236/the-treatment-of-hidradenitis-suppurativa-with-the-glucagon-like-peptide-1-agonist-liraglutide
#9
L Jennings, L Nestor, O Molloy, R Hughes, B Moriarty, B Kirby
Hidradenitis suppurativa (HS) is a cutaneous disease associated with systemic inflammation, obesity and metabolic syndrome. Effective treatment options are limited. The anti-diabetic agents, incretins, have been used successfully to treat psoriasis - a disease also associated with metabolic syndrome. We report the use of liraglutide, a glucagon-like peptide -1 agonist, in a patient with HS, leading to subsequent weight loss and improvement in disease control. To our knowledge, this is the first report of liraglutide used in the treatment of HS...
December 11, 2016: British Journal of Dermatology
https://www.readbyqxmd.com/read/27936966/liraglutide-for-weight-management-benefits-and-risks
#10
Brian Tomlinson, Miao Hu, Yuzhen Zhang, Paul Chan, Zhong-Min Liu
The article by Bays et al. in this issue of the journal describes an interesting analysis of the weight loss dependent and weight loss independent mechanisms for the improvement in cardiometabolic parameters with high dose liraglutide in 3 studies in overweight and obese adults with or without type 2 diabetes mellitus (T2DM) and with or without obstructive sleep apnea.
December 12, 2016: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/27878211/liraglutide-enhances-the-efficacy-of-human-mesenchymal-stem-cells-in-preserving-islet-%C3%AE-cell-function-in-severe-non-obese-diabetic-mice
#11
Li-Rong Li, Xiao-Lei Jia, Hui Hui, Jie Zhang, Ying Liu, Wei-Juan Cui, Qian-Yue Xu, Da-Long Zhu
Glucagon-like peptide 1 (GLP-1) can promote islet β-cell replication and function, and mesenchymal stem cells (MSCs) can inhibit T cell autoimmunity. This study aimed at testing the dynamic distribution of infused human MSCs and therapeutic effect of combined MSCs and Liraglutide, a long-acting GLP-1 analogue, on preserving β-cell function in severe non-obese diabetic (NOD) mice. We found that infused MSCs accumulated in the pancreas at 4 weeks post infusion, which was not affected by Liraglutide treatment...
November 17, 2016: Molecular Medicine
https://www.readbyqxmd.com/read/27835589/liraglutide-suppresses-obesity-and-induces-brown-fat-like-phenotype-via-soluble-guanylyl-cyclase-mediated-pathway-in-vivo-and-in-vitro
#12
Endong Zhu, Yang Yang, Juanjuan Zhang, Yongmei Li, Chunjun Li, Liming Chen, Bei Sun
Strategies for driving white adipose tissue (WAT) to acquire brown-like characteristics are a promising approach to reduce obesity. Liraglutide has been reported to active brown adipose tissue (BAT) thermogenesis and WAT browning by rapid intracerebroventricular injection in mice. In this study, we investigated the effects and possible mechanisms of liraglutide on WAT browning by chronic treatment. Here, we show that liraglutide significantly decreases body weight of mice and reduces the size of white adipocytes...
November 7, 2016: Oncotarget
https://www.readbyqxmd.com/read/27832452/clinical-pharmacokinetics-and-pharmacodynamics-of-antihyperglycemic-medications-in-children-and-adolescents-with-type-2-diabetes-mellitus
#13
REVIEW
Fatemeh Akhlaghi, Kelly L Matson, Amir Hooshang Mohammadpour, Meghan Kelly, Asieh Karimani
The incidence of type 2 diabetes mellitus (T2DM) among children and adolescents has been rising. This condition is associated with obesity, and it's prevalence is higher among minority or female youth. Lifestyle modification including diet and exercise is only successful in a small proportion of patients; therefore, pharmacotherapy approaches are needed to treat T2DM among youth. Currently, in the USA, only metformin and insulin are approved for the treatment of T2DM in children. However, several antihyperglycemic agents including exenatide, glimepiride, glyburide, liraglutide, pioglitazone, and rosiglitazone are also used off-label in this population...
November 10, 2016: Clinical Pharmacokinetics
https://www.readbyqxmd.com/read/27808050/-pharmacotherapy-for-obesity
#14
Jens Meldgaard Bruun
Obesity is a chronic condition, which is why pharmacotherapy can be considered, if lifestyle modification (hypocaloric diet/exercise) does not result in a weight loss of at least 5%. Pharmacotherapy is indicated, if an individual has a BMI > 30 kg/m(2) or a BMI > 27 kg/m(2) and concomitant disease (e.g. Type 2 diabetes), and can be liraglutide (3 mg) or orlistat (120 mg/60 mg). Choice of treatment must be based on patient preferences and clinical situation, side effects, contraindications and financial considerations...
October 31, 2016: Ugeskrift for Laeger
https://www.readbyqxmd.com/read/27804269/early-weight-loss-with-liraglutide-3-0-mg-predicts-1-year-weight-loss-and-is-associated-with-improvements-in-clinical-markers
#15
Ken Fujioka, Patrick M O'Neil, Melanie Davies, Frank Greenway, David C W Lau, Birgitte Claudius, Trine Vang Skjøth, Christine Bjørn Jensen, John P H Wilding
OBJECTIVE: To identify an early response criterion for predicting ≥5% weight loss with liraglutide 3.0 mg at week 56 and to compare efficacy outcomes in early responders (ERs) and early nonresponders (ENRs). METHODS: Using pooled data from the SCALE Obesity and Prediabetes and SCALE Diabetes trials, weight loss of ≥4% at 16 weeks best predicted ≥5% weight loss after 56 weeks. Weight loss and changes in cardiometabolic risk factors and health-related quality of life were evaluated in ERs (≥4% weight loss at week 16) and ENRs (<4% weight loss at week 16) completing 56 weeks' treatment...
November 2016: Obesity
https://www.readbyqxmd.com/read/27773782/obesity-current-and-potential-pharmacotherapeutics-and-targets
#16
REVIEW
Vidya Narayanaswami, Linda P Dwoskin
Obesity is a global epidemic that contributes to a number of health complications including cardiovascular disease, type 2 diabetes, cancer and neuropsychiatric disorders. Pharmacotherapeutic strategies to treat obesity are urgently needed. Research over the past two decades has increased substantially our knowledge of central and peripheral mechanisms underlying homeostatic energy balance. Homeostatic mechanisms involve multiple components including neuronal circuits, some originating in hypothalamus and brain stem, as well as peripherally-derived satiety, hunger and adiposity signals that modulate neural activity and regulate eating behavior...
October 20, 2016: Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/27730066/long-term-efficacy-of-liraglutide-in-indian-patients-with-type-2-diabetes-in-a-real-world-setting
#17
Parjeet Kaur, Shama Mahendru, Ambrish Mithal
BACKGROUND: Long-term efficacy of liraglutide, a glucagon-like peptide-1 analog, on body weight and glycemic control has not been studied in Indian Type 2 diabetes mellitus (T2DM) subjects. AIM: To evaluate the effect of liraglutide on glycemic control and body weight for 1 year in Indian T2DM patients. METHODS: Liraglutide was prescribed to 96 obese patients with T2DM and followed up for 1 year. Clinical parameters were measured at baseline and 3, 6, 9, and 12 months...
September 2016: Indian Journal of Endocrinology and Metabolism
https://www.readbyqxmd.com/read/27718159/reward-induced-eating-therapeutic-approaches-to-addressing-food-cravings
#18
REVIEW
Candida J Rebello, Frank L Greenway
The homeostatic controls over eating are inextricably linked to the reward aspects of eating. The result is an integrated response that coordinates the internal milieu with the prevailing environment. Thus, appetite, which reflects a complex interaction among the external environment, behavioral profile, and subjective states as well as the storage and metabolism of energy, has an important role in the regulation of energy balance. In the prevailing food environment which offers an abundance of food choices it is likely that the motivation to consume from a wide range of delectable foods plays a greater role in contributing to overeating than in the past when the motivation to eat was largely governed by metabolic need...
November 2016: Advances in Therapy
https://www.readbyqxmd.com/read/27717126/near-normalization-of-glycaemic-control-with-glucagon-like-peptide-1-receptor-agonist-treatment-combined-with-exercise-in-patients-with-type-2-diabetes
#19
P Mensberg, S Nyby, P G Jørgensen, H Storgaard, M T Jensen, J Sivertsen, J J Holst, B Kiens, E A Richter, F K Knop, T Vilsbøll
AIMS: To investigate the effects of exercise in combination with a glucagon-like peptide-1 receptor agonist (GLP-1RA), liraglutide, or placebo for the treatment of type 2 diabetes. METHODS: Thirty-three overweight, dysregulated and sedentary patients with type 2 diabetes were randomly allocated to 16 weeks of either exercise and liraglutide or exercise and placebo. Both groups had three supervised 60-minute training sessions per week including spinning and resistance training...
September 26, 2016: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/27711029/adipose-tissue-obesity-and-nonalcoholic-fatty-liver-disease
#20
Stergios A Polyzos, Jannis Kountouras, Christos S Mantzoros
The association of obesity with nonalcoholic fatty liver disease (NAFLD) has been established. Obesity has been linked not only to initial stages of the disease, i.e., simple steatosis (SS), but also to its severity. Form an epidemiologic point of view, both diseases has an increasing prevalence worldwide. From a pathogenetic point of view, obesity and its associate IR contribute to the initial fat accumulation in the hepatocyte (SS), but also to the progression of SS to nonalcoholic steatohepatitis (NASH), NASH-related cirrhosis and hepatocellular carcinoma (HCC)...
October 6, 2016: Minerva Endocrinologica
keyword
keyword
107467
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"